MA27590A1 - Agonistes du recepteur du facteur de liberation 2 de la corticotropine. - Google Patents

Agonistes du recepteur du facteur de liberation 2 de la corticotropine.

Info

Publication number
MA27590A1
MA27590A1 MA27778A MA27778A MA27590A1 MA 27590 A1 MA27590 A1 MA 27590A1 MA 27778 A MA27778 A MA 27778A MA 27778 A MA27778 A MA 27778A MA 27590 A1 MA27590 A1 MA 27590A1
Authority
MA
Morocco
Prior art keywords
receptor agonists
release factor
corticotropin release
corticotropin
derivatives
Prior art date
Application number
MA27778A
Other languages
English (en)
Inventor
Robert Joseph Isfort
Wieslaw Adam Mazur
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of MA27590A1 publication Critical patent/MA27590A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57509—Corticotropin releasing factor [CRF] (Urotensin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne des dérivés isolés du facteur de libération de corticotropine, et des acides nucléiques codant pour de tels dérivés, efficaces dans le traitement de troubles modulés par le récepteur du facteur 2 de libération de la corticotropine tels que la dystrophie musculaire.
MA27778A 2002-01-16 2004-07-13 Agonistes du recepteur du facteur de liberation 2 de la corticotropine. MA27590A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US34911702P 2002-01-16 2002-01-16
US37633702P 2002-04-29 2002-04-29
US38889502P 2002-06-14 2002-06-14
US41198802P 2002-09-19 2002-09-19

Publications (1)

Publication Number Publication Date
MA27590A1 true MA27590A1 (fr) 2005-11-01

Family

ID=27617822

Family Applications (3)

Application Number Title Priority Date Filing Date
MA27780A MA27592A1 (fr) 2002-01-16 2004-07-13 Agonistes du recepteur du facteur de liberation 2 de la corticotropine.
MA27779A MA27591A1 (fr) 2002-01-16 2004-07-13 Agonistes du recepteur du facteur de liberation 2 de la corticotropine.
MA27778A MA27590A1 (fr) 2002-01-16 2004-07-13 Agonistes du recepteur du facteur de liberation 2 de la corticotropine.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
MA27780A MA27592A1 (fr) 2002-01-16 2004-07-13 Agonistes du recepteur du facteur de liberation 2 de la corticotropine.
MA27779A MA27591A1 (fr) 2002-01-16 2004-07-13 Agonistes du recepteur du facteur de liberation 2 de la corticotropine.

Country Status (29)

Country Link
US (7) US7192924B2 (fr)
EP (4) EP1465921B1 (fr)
JP (3) JP4508648B2 (fr)
KR (3) KR100758857B1 (fr)
CN (3) CN100475844C (fr)
AR (3) AR038142A1 (fr)
AT (4) ATE362488T1 (fr)
AU (2) AU2003205197B2 (fr)
BR (3) BR0306826A (fr)
CA (3) CA2470656C (fr)
CY (1) CY1106133T1 (fr)
DE (4) DE60318547T2 (fr)
DK (2) DK1465921T3 (fr)
ES (4) ES2309909T3 (fr)
IL (5) IL162529A0 (fr)
MA (3) MA27592A1 (fr)
MX (3) MXPA04006884A (fr)
MY (1) MY140306A (fr)
NO (3) NO20043371L (fr)
NZ (3) NZ533599A (fr)
PE (3) PE20030849A1 (fr)
PL (3) PL371364A1 (fr)
PT (2) PT1465921E (fr)
RU (1) RU2294333C2 (fr)
SA (3) SA03230565B1 (fr)
SI (1) SI1465921T1 (fr)
TW (3) TW200302278A (fr)
WO (3) WO2003062268A2 (fr)
ZA (1) ZA200404995B (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002024732A2 (fr) * 2000-09-22 2002-03-28 Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften Methodes permettant d'ameliorer les proprietes antagonistes/agonistes des antagonistes/agonistes peptidiques du recepteur de la corticoliberine (crfr)
US7192924B2 (en) * 2002-01-16 2007-03-20 The Procter & Gamble Company Corticotropin releasing factor 2 receptor agonists
WO2005103690A2 (fr) * 2004-04-24 2005-11-03 Bayer Healthcare Ag Diagnostic et therapeutique de maladies associees au recepteur de l'hormone de liberation de la corticotropine 2 (crhr2)
CN101687025A (zh) * 2005-03-30 2010-03-31 诺华疫苗和诊断公司 B型流感嗜血杆菌
US7815905B2 (en) 2006-01-27 2010-10-19 Research Development Foundation Methods of increasing insulin sensitivity or decreasing insulin secretion by administering corticotropin releasing factor receptor-2 inhibitors
WO2009046874A1 (fr) * 2007-09-11 2009-04-16 Mondobiotech Laboratories Ag Polythérapie de peptide potentialisateur de la trh et de stresscopine
KR20100056507A (ko) * 2007-09-11 2010-05-27 몬도바이오테크 래보래토리즈 아게 치료제로서의 펩티드 ｐｒｏ－ｇｌｙ－ｔｈｒ－ｃｙｓ－ｇｌｕ－ｉｌｅ－ｃｙｓ－ａｌａ－ｔｙｒ－ａｌａ－ａｌａ－ｃｙｓ－ｔｈｒ－ｇｌｙ－ｃｙｓ의 용도
EP2190533A2 (fr) * 2007-09-11 2010-06-02 Mondobiotech Laboratories AG Utilisation d'un peptide en tant qu'agent thérapeutique
SG171957A1 (en) * 2008-11-04 2011-07-28 Janssen Pharmaceutica Nv Crhr2 peptide agonists and uses thereof
EP2206726A1 (fr) * 2009-01-08 2010-07-14 Universite Joseph Fourier Outils non invasifs pour la détection de plaques athérosclérotique vulnérables
US20110105397A1 (en) * 2009-11-04 2011-05-05 Gengo Peter J Method for treating heart failure with stresscopin-like peptides
WO2013063046A1 (fr) 2011-10-24 2013-05-02 Research Development Foundation Procédés d'augmentation de la sécrétion d'insuline par costimulation des récepteurs du facteur de libération de la corticotropine
CN108310396B (zh) 2012-02-14 2022-07-15 加利福尼亚大学董事会 用于心血管疾病和其它病况的旁分泌基因的全身性递送和受调节的表达
JOP20170153A1 (ar) * 2016-07-15 2019-01-30 Lilly Co Eli نظائر urocortin-2 جديدة معدلة بحمض دهني لعلاج داء السكري وأمراض الكلى المزمنة
AU2017345785A1 (en) * 2016-10-20 2019-05-16 Cortene Inc. Methods of treating diseases resulting from a maladapted stress response
CN110755434B (zh) * 2018-07-27 2022-03-15 中国医学科学院药物研究所 化合物palosuran防治骨骼肌萎缩等疾病的用途
WO2025184558A1 (fr) * 2024-02-28 2025-09-04 Caradon Therapeutics, Inc. Urocortine 3 modifiée
TW202544027A (zh) * 2024-04-19 2025-11-16 美商紐羅克里生物科學有限公司 促皮質素釋放因子受體２（ｃｒｆｒ２）促效劑
AU2025204485B2 (en) * 2024-04-30 2025-12-11 Hanmi Pharm. Co. Ltd. Use of crf2 receptor agonist and the acylated conjugates thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5235036A (en) 1991-05-31 1993-08-10 The Salk Institute For Biological Studies Crf analogs
EP0860501A3 (fr) 1994-06-14 1999-05-19 Neurocrine Biosciences, Inc. Récepteurs du facteur 2 libérant la corticotropine
US5786203A (en) 1994-06-14 1998-07-28 Neurocrine Biosciences, Inc. Isolated nucleic acid encoding corticotropin-releasing factor2 receptors
US5663292A (en) 1994-12-12 1997-09-02 The Salk Institute For Biological Studies Cyclic CRF analogs
US5824771A (en) 1994-12-12 1998-10-20 The Salk Institute For Biological Studies Cyclic CRF agonists
US5660824A (en) 1995-05-24 1997-08-26 Grabstein; Kenneth H. Muscle trophic factor
EP0845035A2 (fr) 1995-06-13 1998-06-03 The Salk Institute For Biological Studies Peptides d'urocortine
US5869450A (en) * 1996-03-06 1999-02-09 The Regents Of The University Of California Anti-inflammatory compositions and method with corticotropin-releasing factor analogs
DK1305334T3 (da) 2000-08-04 2009-02-02 Res Dev Foundation Urocortinproteiner og anvendelser deraf
WO2002024732A2 (fr) * 2000-09-22 2002-03-28 Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften Methodes permettant d'ameliorer les proprietes antagonistes/agonistes des antagonistes/agonistes peptidiques du recepteur de la corticoliberine (crfr)
US20020082409A1 (en) 2000-10-26 2002-06-27 Hsu Sheau Yu Stresscopins and their uses
US6670140B2 (en) * 2001-03-06 2003-12-30 The Procter & Gamble Company Methods for identifying compounds for regulating muscle mass or function using corticotropin releasing factor receptors
US7192924B2 (en) * 2002-01-16 2007-03-20 The Procter & Gamble Company Corticotropin releasing factor 2 receptor agonists

Also Published As

Publication number Publication date
CA2470743C (fr) 2011-12-13
DE60307044D1 (de) 2006-09-07
IL162530A0 (en) 2005-11-20
EP1724283A3 (fr) 2007-04-11
US20060025339A1 (en) 2006-02-02
ES2287484T3 (es) 2007-12-16
PT1465921E (pt) 2006-12-29
ATE383372T1 (de) 2008-01-15
SA03230564B1 (ar) 2006-10-31
IL162431A0 (en) 2005-11-20
JP4508648B2 (ja) 2010-07-21
SA03230565A (ar) 2005-12-03
NZ533598A (en) 2007-03-30
PE20030849A1 (es) 2003-12-01
IL162529A0 (en) 2005-11-20
JP2005522191A (ja) 2005-07-28
RU2294333C2 (ru) 2007-02-27
WO2003062268A3 (fr) 2003-11-27
EP1465921A2 (fr) 2004-10-13
DK1465923T3 (da) 2007-07-02
WO2003062277A1 (fr) 2003-07-31
KR100735586B1 (ko) 2007-07-04
CA2470656A1 (fr) 2003-07-31
AU2003205197B2 (en) 2006-03-02
SA03230565B1 (ar) 2006-10-31
JP2005521387A (ja) 2005-07-21
ES2299701T3 (es) 2008-06-01
ATE334147T1 (de) 2006-08-15
AR038142A1 (es) 2004-12-29
RU2004124847A (ru) 2005-04-20
IL196384A0 (en) 2011-07-31
SI1465921T1 (sl) 2006-10-31
AR038144A1 (es) 2004-12-29
CA2470656C (fr) 2011-06-28
KR20040082389A (ko) 2004-09-24
US20100197579A1 (en) 2010-08-05
CY1106133T1 (el) 2011-06-08
CN100475844C (zh) 2009-04-08
IL197774A0 (en) 2009-12-24
US20030148957A1 (en) 2003-08-07
ES2269976T3 (es) 2007-04-01
JP4489434B2 (ja) 2010-06-23
MXPA04006885A (es) 2004-12-06
US20030148956A1 (en) 2003-08-07
DE60313845T2 (de) 2008-01-31
NO20043371L (no) 2004-10-06
US7897731B2 (en) 2011-03-01
TW200302278A (en) 2003-08-01
US20090124793A1 (en) 2009-05-14
CN100391972C (zh) 2008-06-04
ZA200404995B (en) 2005-06-29
US7192924B2 (en) 2007-03-20
EP1724283A2 (fr) 2006-11-22
DE60318547D1 (de) 2008-02-21
CN1617887A (zh) 2005-05-18
DE60318547T2 (de) 2008-12-24
EP1465921B1 (fr) 2006-07-26
TW200302276A (en) 2003-08-01
BR0306838A (pt) 2005-04-05
CA2470731A1 (fr) 2003-07-31
US7192923B2 (en) 2007-03-20
CN1617885A (zh) 2005-05-18
KR100758857B1 (ko) 2007-09-14
PE20030747A1 (es) 2003-10-23
CN1617886A (zh) 2005-05-18
JP4508649B2 (ja) 2010-07-21
DE60321730D1 (de) 2008-07-31
AR038143A1 (es) 2004-12-29
ES2309909T3 (es) 2008-12-16
CA2470731C (fr) 2011-06-21
DE60313845D1 (de) 2007-06-28
TW200302277A (en) 2003-08-01
US20080004435A1 (en) 2008-01-03
EP1465922A2 (fr) 2004-10-13
DE60307044T2 (de) 2007-02-15
MA27591A1 (fr) 2005-11-01
AU2003237419B2 (en) 2006-04-13
EP1465922B1 (fr) 2008-01-09
US7632933B2 (en) 2009-12-15
KR20040082390A (ko) 2004-09-24
MA27592A1 (fr) 2005-11-01
TWI300442B (en) 2008-09-01
US6936585B2 (en) 2005-08-30
EP1724283B1 (fr) 2008-06-18
JP2005525101A (ja) 2005-08-25
SA03230564A (ar) 2005-12-03
PT1465923E (pt) 2007-08-06
CA2470743A1 (fr) 2003-07-31
US7608701B2 (en) 2009-10-27
KR20040082392A (ko) 2004-09-24
DK1465921T3 (da) 2006-11-27
MXPA04006884A (es) 2004-12-06
PL373529A1 (en) 2005-09-05
MY140306A (en) 2009-12-31
BR0306826A (pt) 2005-09-06
ATE398632T1 (de) 2008-07-15
EP1465923B1 (fr) 2007-05-16
PE20030974A1 (es) 2003-12-26
US7462597B2 (en) 2008-12-09
BR0306878A (pt) 2004-10-26
NZ533600A (en) 2007-02-23
ATE362488T1 (de) 2007-06-15
US20030148958A1 (en) 2003-08-07
WO2003062269A3 (fr) 2003-11-06
EP1465923A1 (fr) 2004-10-13
WO2003062269A2 (fr) 2003-07-31
KR100758858B1 (ko) 2007-09-14
WO2003062268A2 (fr) 2003-07-31
HK1078095A1 (zh) 2006-03-03
PL373139A1 (en) 2005-08-22
MXPA04006883A (es) 2004-12-06
NO20043366L (no) 2004-10-06
PL371364A1 (en) 2005-06-13
NZ533599A (en) 2007-03-30
NO20043396L (no) 2004-10-06

Similar Documents

Publication Publication Date Title
MA27590A1 (fr) Agonistes du recepteur du facteur de liberation 2 de la corticotropine.
MA29444B1 (fr) Antagonistes npy, preparation et utilisations
MA27334A1 (fr) Utilisation d'inhibiteurs de l'ikb kinase dans le traitement de la douleur
MA27668A1 (fr) 2,4-di(phenylamino) pyrimidines utilisees pour traiter des maladies neoplasiques, des troubles inflammatoires et des troubles du systeme immunitaire
MA29692B1 (fr) Derives de la xanthine en tant qu'agonistes selectifs du hm74a
DE602004024572D1 (de) Zusammensetzungen, die sich als inhibitoren von proteinkinasen eignen
SG127739A1 (en) Use of immuno-regulators
MA30696B1 (fr) Derives de l'acide (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetique
MA29772B1 (fr) Benzimidazoles substitues et procedes de preparation
EP1638950A4 (fr) Derives de cyclohexylglycine servant d'inhibiteurs de la dipeptidyl peptidase pour le traitement ou la prevention du diabete
MA32014B1 (fr) Composes condenses de pyridine, de pyrimidine et de triazine en tant qu'inhibiteurs du cycle cellulaire
TNSN98017A1 (fr) Derives de sulfonyluree, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA27863A1 (fr) Forme posologique à libération prolongée d'anesthésiques pour le traitement de la douleur
BRPI0414435A (pt) métodos e reagentes para o tratamento de distúrbios imunoinflamatórios
WO2003104425A3 (fr) Nouveaux anticorps anti-cd22 stables
MA27771A1 (fr) 5,7-diaminopyrazolo[4,3-d]pyrimidines utiles dans le traitement de l'hypertension
DE60206198T2 (de) Tetrahydrochinolinderivate als muscarinische agonisten
MA27509A1 (fr) Formulations a liberation prolongee contenant de la lamotrigine
EP1505990A4 (fr) Methodes de traitement de l'hepatite
DE69920017D1 (de) Neue form vom irbesartan, verfahren um diese form zu erhalten und sie enthaltende pharmazeutische zusammensetzungen
MA29787B1 (fr) Traitement de maladies auto-immunes
MA31198B1 (fr) Nouvelle forme dosifiee
MA29723B1 (fr) Composes
MA28038A1 (fr) Thienopyrazoles
DE60226906D1 (de) 3,6-disubstituierte azabicyclo ä3.1.0ühexanderivate, die sich als muscarinrezeptorantagonisten eignen